Doseology Sciences Inc. (DOSEF)
USD 0.14
(0.0%)
USD 0.14
(0.0%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 43.08 Thousand | 16.04 Thousand | - |
| Cost of Revenue | 1802.00 | 164.42 Thousand | - |
| Gross Profit | 41.28 Thousand | -148.37 Thousand | - |
| Operating Expenses | 873.45 Thousand | 1.66 Million | 1.56 Million |
| Selling, General and Administrative Expenses | 759.77 Thousand | 1.46 Million | 1.36 Million |
| Research and Development Expenses | 500.00 | 61.72 Thousand | 112.4 Thousand |
| Other Expenses | - | - | - |
| Cost and Expenses | 875.26 Thousand | 1.83 Million | 1.56 Million |
| Operating Income | -767.13 Thousand | -1.8 Million | -1.56 Million |
| Interest Expense | 36.13 Thousand | 75.77 Thousand | 68.29 Thousand |
| Income Tax Expense | 36.13 Thousand | 75.77 Thousand | 68.29 Thousand |
| Earnings before Tax | -1.78 Million | -1.93 Million | -1.62 Million |
| Net Income | -1.78 Million | -1.93 Million | -1.62 Million |
| Earnings Per Share Basic | -0.04 | -0.05 | -0.04 |
| Earnings Per Share Diluted | -0.04 | -0.05 | -0.04 |
| Weighted Average Shares Outstanding | 41.1 Million | 39.09 Million | 41 Million |
| Weighted Average Shares Outstanding (Diluted) | 41.1 Million | 39.09 Million | 41 Million |
| Gross Margin | 0.96 | -9.25 | - |
| EBIT Margin | -16.27 | -104.08 | - |
| Profit Margin | -41.35 | -120.85 | - |
| EBITDA | -1.72 Million | -1.67 Million | -1.47 Million |
| Earnings Before Tax Margin | -17.80 | -112.77 | - |
| Breakdown | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 | 2022 Q3 | 2022 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 13.27 Thousand | 46.1 Thousand | 43.08 Thousand | 11.05 Thousand | 9808.00 | 17.05 Thousand |
| Cost of Revenue | 20.47 Thousand | 17.28 Thousand | 1802.00 | -27.28 Thousand | 7358.00 | 11.25 Thousand |
| Gross Profit | -7201.00 | 28.81 Thousand | 41.28 Thousand | 38.34 Thousand | 2450.00 | 5805.00 |
| Operating Expenses | 131.66 Thousand | 113.24 Thousand | 873.45 Thousand | 130.79 Thousand | 152.99 Thousand | 286.73 Thousand |
| Selling, General and Administrative Expenses | 131.66 Thousand | 80.91 Thousand | - | 229.18 Thousand | 87.75 Thousand | 258.67 Thousand |
| Research and Development Expenses | - | - | - | 500.00 | - | - |
| Other Expenses | - | - | - | - | 23.28 Thousand | - |
| Cost and Expenses | 152.14 Thousand | 130.52 Thousand | 875.26 Thousand | 103.5 Thousand | 160.35 Thousand | 297.99 Thousand |
| Operating Income | -138.87 Thousand | -78.08 Thousand | -767.13 Thousand | -96.36 Thousand | -87.05 Thousand | -266.82 Thousand |
| Interest Expense | - | - | 36.13 Thousand | -18.54 Thousand | 17.71 Thousand | 18.23 Thousand |
| Income Tax Expense | 3.00 | 6344.00 | 36.13 Thousand | 65.98 Thousand | 41 Thousand | -96.76 Thousand |
| Earnings before Tax | -111.64 Thousand | -78.08 Thousand | -1.78 Million | -1.05 Million | -110.56 Thousand | -188.29 Thousand |
| Net Income | -111.64 Thousand | -78.08 Thousand | -1.78 Million | -1.14 Million | -110.56 Thousand | -188.29 Thousand |
| Earnings Per Share Basic | -0.03 | -0.00 | - | -0.28 | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.03 | -0.00 | - | -0.28 | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 4.4 Million | 41.1 Million | 41.1 Million | 4.11 Million | 41.1 Million | 41.1 Million |
| Weighted Average Shares Outstanding (Diluted) | 4.4 Million | 41.1 Million | 41.1 Million | 4.11 Million | 41.1 Million | 41.1 Million |
| Gross Margin | -0.54 | 0.63 | 0.96 | 3.47 | 0.25 | 0.34 |
| EBIT Margin | -10.40 | -1.30 | - | -10.36 | -6.02 | -14.00 |
| Profit Margin | -8.41 | -1.69 | -41.35 | -103.72 | -11.27 | -11.04 |
| EBITDA | -138.07 Thousand | -60.1 Thousand | - | -114.6 Thousand | -59.07 Thousand | -238.75 Thousand |
| Earnings Before Tax Margin | -10.46 | -1.69 | -17.80 | -8.71 | -8.88 | -15.64 |
EDEN
ORDS
FOG
5237
600977
SEQUENT